(0.27%) 5 113.73 points
(0.38%) 38 383 points
(0.33%) 15 980 points
(-1.67%) $82.45
(4.84%) $2.02
(0.29%) $2 353.90
(0.21%) $27.59
(4.07%) $959.65
(-0.19%) $0.933
(-0.33%) $10.99
(-0.52%) $0.796
(1.70%) $93.44
-0.02% ¥ 4 089.00
Live Chart Being Loaded With Signals
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally...
Stats | |
---|---|
Dagens volum | 3.19M |
Gjennomsnittsvolum | 4.48M |
Markedsverdi | 6 415.37B |
EPS | ¥0 ( 2024-02-01 ) |
Neste inntjeningsdato | ( ¥1.100 ) 2024-05-08 |
Last Dividend | ¥90.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 36.36 |
ATR14 | ¥1.540 (0.04%) |
Volum Korrelasjon
Takeda Pharmaceutical Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Takeda Pharmaceutical Korrelasjon - Valuta/Råvare
Takeda Pharmaceutical Økonomi
Annual | 2022 |
Omsetning: | ¥4 027.48B |
Bruttogevinst: | ¥2 783.41B (69.11 %) |
EPS: | ¥204.29 |
FY | 2022 |
Omsetning: | ¥4 027.48B |
Bruttogevinst: | ¥2 783.41B (69.11 %) |
EPS: | ¥204.29 |
FY | 2022 |
Omsetning: | ¥3 569.01B |
Bruttogevinst: | ¥2 462.16B (68.99 %) |
EPS: | ¥147.14 |
FY | 2021 |
Omsetning: | ¥3 197.81B |
Bruttogevinst: | ¥2 203.50B (68.91 %) |
EPS: | ¥240.72 |
Financial Reports:
No articles found.
Takeda Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥90.00 (N/A) |
¥0 (N/A) |
¥90.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥16.50 | 2000-03-28 |
Last Dividend | ¥90.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 48 | -- |
Total Paid Out | ¥3 458.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.84 | -- |
Div. Sustainability Score | 4.76 | |
Div.Growth Potential Score | 4.33 | |
Div. Directional Score | 4.54 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
7976.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
7212.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
6458.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5464.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4461.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3641.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2897.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
1716.T | Ex Dividend Knight | 2024-06-27 | Annually | 0 | 0.00% | |
9308.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8285.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0427 | 1.500 | 9.15 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0125 | 1.200 | 9.58 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0263 | 1.500 | -0.819 | -1.228 | [0.1 - 1] |
payoutRatioTTM | 1.619 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.064 | 0.800 | 9.68 | 7.74 | [1 - 3] |
quickRatioTTM | 0.465 | 0.800 | -1.972 | -1.578 | [0.8 - 2.5] |
cashRatioTTM | 0.126 | 1.500 | -0.409 | -0.614 | [0.2 - 2] |
debtRatioTTM | 0.328 | -1.500 | 4.53 | -6.80 | [0 - 0.6] |
interestCoverageTTM | 1.450 | 1.000 | -0.574 | -0.574 | [3 - 30] |
operatingCashFlowPerShareTTM | 466.22 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -82.25 | 2.00 | -10.00 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 0.692 | -1.500 | 7.23 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.675 | 1.000 | 2.08 | 2.08 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0750 | 1.000 | -0.500 | -0.500 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.157 | 1.000 | -0.240 | -0.240 | [0.2 - 2] |
assetTurnoverTTM | 0.293 | 0.800 | -1.379 | -1.103 | [0.5 - 2] |
Total Score | 4.76 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 36.00 | 1.000 | 6.47 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0263 | 2.50 | -0.526 | -1.228 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -82.25 | 2.00 | -10.00 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.60 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 466.22 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.619 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.927 | 1.500 | 7.15 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.175 | 1.000 | 8.11 | 0 | [0.1 - 0.5] |
Total Score | 4.33 |
Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.